Payment overview · 2025
General Payments
$150.43
7 reported records · 3 companies
Healthcare provider profile · identity verified
Michael Plokamakis, M.D.
Allopathic & Osteopathic Physicians|Internal Medicine · ASTORIA, NY · NPI 1033205117
Verified facts
What the public records show
CMS Open Payments records show Michael Plokamakis, M.D. received $150.43 in general payments during 2025 across 7 reported records.
Exact Sciences Corporation accounted for 72.3% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 4 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Ozempic.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported FARXIGA as an associated drug or biological on 106133 records involving 42906 distinct recipient NPIs. Public Medicare Part D data also shows 150 claims for Farxiga by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYMBICORT as an associated drug or biological on 71 records involving 51 distinct recipient NPIs. Public Medicare Part D data also shows 58 claims for Symbicort by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Ozempic as an associated drug or biological on 261625 records involving 77793 distinct recipient NPIs. Public Medicare Part D data also shows 106 claims for Ozempic by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| Exact Sciences Corporation | Unresolved — no canonical attribution shown | $108.83 | 72.3% | 5 | 2025 |
| AstraZeneca Pharmaceuticals LP | Unresolved — no canonical attribution shown | $24.90 | 16.6% | 1 | 2025 |
| Novo Nordisk Inc | Unresolved — no canonical attribution shown | $16.70 | 11.1% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $150.43 | 7 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| Cologuard Collection Kit Normalized: cologuard collection kit |
Device | Exact Sciences Corporation | $108.83 | 5 | 2025 |
Source payment records
|
|||||
| AIRSUPRA Normalized: airsupra |
Drug | AstraZeneca Pharmaceuticals LP | $24.90 | 1 | 2025 |
Source payment records
|
|||||
| Ozempic Normalized: ozempic |
Drug | Novo Nordisk Inc | $16.70 | 1 | 2025 |
Source payment records
|
|||||
| Rybelsus Normalized: rybelsus |
Drug | Novo Nordisk Inc | $16.70 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| Ozempic ozempic |
2025 | Ozempic | 2024 | 106 | exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | FARXIGA open payments reported associated product |
CMS Open Payments — General Payments 106133 supporting records · 42906 recipient NPIs · example record 1206131362 |
Farxiga · 2024 Exact normalized brand match · 1 Part D row |
150 | 38 |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | SYMBICORT open payments reported associated product |
CMS Open Payments — General Payments 71 supporting records · 51 recipient NPIs · example record 1206132610 |
Symbicort · 2024 Exact normalized brand match · 1 Part D row |
58 | 19 |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Ozempic open payments reported associated product |
CMS Open Payments — General Payments 261625 supporting records · 77793 recipient NPIs · example record 1188130076 |
Ozempic · 2024 Exact normalized brand match · 1 Part D row |
106 | 24 |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Atorvastatin Calcium | Atorvastatin Calcium | 1596 | 509 |
| Amlodipine Besylate | Amlodipine Besylate | 1047 | 328 |
| Losartan Potassium | Losartan Potassium | 793 | 241 |
| Metformin Hcl | Metformin Hcl | 738 | 221 |
| Metoprolol Succinate | Metoprolol Succinate | 632 | 183 |
| Levothyroxine Sodium | Levothyroxine Sodium | 518 | 151 |
| Omeprazole | Omeprazole | 468 | 149 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 417 | 135 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 412 | 157 |
| Tamsulosin Hcl | Tamsulosin Hcl | 394 | 126 |
| Eliquis | Apixaban | 352 | 73 |
| Lisinopril | Lisinopril | 341 | 107 |
| Simvastatin | Simvastatin | 330 | 96 |
| Furosemide | Furosemide | 245 | 76 |
| Famotidine | Famotidine | 222 | 70 |
| Clopidogrel | Clopidogrel Bisulfate | 214 | 64 |
| Gabapentin | Gabapentin | 214 | 93 |
| Meclizine Hcl | Meclizine Hcl | 197 | 77 |
| Pantoprazole Sodium | Pantoprazole Sodium | 197 | 71 |
| Prednisone | Prednisone | 195 | 97 |
| Fluticasone Propionate | Fluticasone Propionate | 177 | 81 |
| Zolpidem Tartrate | Zolpidem Tartrate | 175 | 38 |
| Januvia | Sitagliptin Phosphate | 168 | 40 |
| Escitalopram Oxalate | Escitalopram Oxalate | 165 | 33 |
| Farxiga | Dapagliflozin Propanediol | 150 | 38 |
| Mirtazapine | Mirtazapine | 146 | 49 |
| Glimepiride | Glimepiride | 142 | 38 |
| Jardiance | Empagliflozin | 140 | 34 |
| Atenolol | Atenolol | 133 | 39 |
| Azithromycin | Azithromycin | 133 | 107 |
| Amlodipine Besylate-Benazepril | Amlodipine Besylate/Benazepril | 126 | 44 |
| Olmesartan Medoxomil | Olmesartan Medoxomil | 125 | 48 |
| Finasteride | Finasteride | 122 | 38 |
| Naproxen | Naproxen | 121 | 49 |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 119 | 39 |
| Methylprednisolone | Methylprednisolone | 118 | 76 |
| Meloxicam | Meloxicam | 114 | 38 |
| Diclofenac Sodium | Diclofenac Sodium | 112 | 41 |
| Ibuprofen | Ibuprofen | 112 | 60 |
| Mupirocin | Mupirocin | 111 | 52 |
| Sertraline Hcl | Sertraline Hcl | 109 | 26 |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 107 | 63 |
| Ozempic | Semaglutide | 106 | 24 |
| Alendronate Sodium | Alendronate Sodium | 104 | 30 |
| Vitamin D2 | Ergocalciferol (Vitamin D2) | 102 | 35 |
| Donepezil Hcl | Donepezil Hcl | 101 | 35 |
| Bisoprolol-Hydrochlorothiazide | Bisoprolol/Hydrochlorothiazide | 95 | 30 |
| Breo Ellipta | Fluticasone/Vilanterol | 95 | 17 |
| Alprazolam | Alprazolam | 93 | 34 |
| Linzess | Linaclotide | 93 | 32 |
| Ezetimibe | Ezetimibe | 92 | 30 |
| Allopurinol | Allopurinol | 87 | 32 |
| Hydrochlorothiazide | Hydrochlorothiazide | 87 | 28 |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 82 | 16 |
| Pravastatin Sodium | Pravastatin Sodium | 81 | 27 |
| Carvedilol | Carvedilol | 73 | 27 |
| Warfarin Sodium | Warfarin Sodium | 73 | 17 |
| Clotrimazole-Betamethasone | Clotrimazole/Betamethasone Dip | 72 | 36 |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 71 | 54 |
| Duloxetine Hcl | Duloxetine Hcl | 71 | 21 |
| Fenofibrate | Fenofibrate Nanocrystallized | 71 | 25 |
| Synthroid | Levothyroxine Sodium | 69 | 21 |
| Memantine Hcl | Memantine Hcl | 66 | 17 |
| Glipizide Er | Glipizide | 65 | 23 |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 65 | 17 |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 62 | 22 |
| Montelukast Sodium | Montelukast Sodium | 62 | 27 |
| Valsartan | Valsartan | 62 | 18 |
| Metformin Hcl Er | Metformin Hcl | 59 | 24 |
| Potassium Chloride | Potassium Chloride | 59 | 18 |
| Ketoconazole | Ketoconazole | 58 | 21 |
| Symbicort | Budesonide/Formoterol Fumarate | 58 | 19 |
| Ventolin Hfa | Albuterol Sulfate | 57 | suppressed |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 56 | 43 |
| Loperamide | Loperamide Hcl | 56 | 13 |
| Ramipril | Ramipril | 53 | 16 |
| Ondansetron Hcl | Ondansetron Hcl | 51 | 22 |
| Colchicine | Colchicine | 50 | 13 |
| Olmesartan-Amlodipine-Hctz | Olmesartan/Amlodipin/Hcthiazid | 50 | 16 |
| Hydrocortisone | Hydrocortisone | 49 | 16 |
| Xarelto | Rivaroxaban | 49 | 12 |
| Labetalol Hcl | Labetalol Hcl | 46 | 14 |
| Clotrimazole | Clotrimazole | 44 | 20 |
| Doxycycline Hyclate | Doxycycline Hyclate | 44 | 34 |
| Nifedipine Er | Nifedipine | 44 | 13 |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 43 | 16 |
| Fluconazole | Fluconazole | 42 | 21 |
| Mometasone Furoate | Mometasone Furoate | 40 | 11 |
| Carbidopa-Levodopa | Carbidopa/Levodopa | 38 | suppressed |
| Celecoxib | Celecoxib | 38 | 14 |
| Triamterene-Hydrochlorothiazid | Triamterene/Hydrochlorothiazid | 38 | 15 |
| Valacyclovir | Valacyclovir Hcl | 38 | 18 |
| Bisoprolol Fumarate | Bisoprolol Fumarate | 37 | 13 |
| Clonazepam | Clonazepam | 37 | 15 |
| Doxazosin Mesylate | Doxazosin Mesylate | 37 | suppressed |
| Irbesartan | Irbesartan | 37 | 11 |
| Myrbetriq | Mirabegron | 36 | 11 |
| Paroxetine Hcl | Paroxetine Hcl | 36 | suppressed |
| Bupropion Hcl Sr | Bupropion Hcl | 35 | suppressed |
| Dexlansoprazole Dr | Dexlansoprazole | 35 | suppressed |
| Glipizide | Glipizide | 35 | 13 |
| Incruse Ellipta | Umeclidinium Bromide | 35 | suppressed |
| Spiriva Handihaler | Tiotropium Bromide | 35 | suppressed |
| Entresto | Sacubitril/Valsartan | 34 | 11 |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 33 | 11 |
| Levofloxacin | Levofloxacin | 32 | 19 |
| Cephalexin | Cephalexin | 31 | 26 |
| Sumatriptan Succinate | Sumatriptan Succinate | 31 | suppressed |
| Valsartan-Hydrochlorothiazide | Valsartan/Hydrochlorothiazide | 31 | 11 |
| Lorazepam | Lorazepam | 30 | suppressed |
| Amiodarone Hcl | Amiodarone Hcl | 29 | 11 |
| Quetiapine Fumarate | Quetiapine Fumarate | 29 | 12 |
| Olmesartan-Hydrochlorothiazide | Olmesartan/Hydrochlorothiazide | 28 | suppressed |
| Paxlovid | Nirmatrelvir/Ritonavir | 28 | 28 |
| Citalopram Hbr | Citalopram Hydrobromide | 27 | suppressed |
| Metoprolol Tartrate | Metoprolol Tartrate | 27 | suppressed |
| Amoxicillin | Amoxicillin | 26 | 19 |
| Basaglar Kwikpen U-100 | Insulin Glargine,hum.Rec.Anlog | 26 | 11 |
| Fluticasone-Salmeterol | Fluticasone Propion/Salmeterol | 26 | suppressed |
| Aripiprazole | Aripiprazole | 25 | suppressed |
| Benazepril Hcl | Benazepril Hcl | 25 | suppressed |
| Janumet | Sitagliptin Phos/Metformin Hcl | 25 | suppressed |
| Neomycin-Polymyxin-Hc | Neomycin/Polymyxin B/Hydrocort | 25 | 21 |
| Oxybutynin Chloride Er | Oxybutynin Chloride | 25 | suppressed |
| Terconazole | Terconazole | 25 | 11 |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 24 | suppressed |
| Tradjenta | Linagliptin | 24 | suppressed |
| Chlorthalidone | Chlorthalidone | 23 | suppressed |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 23 | suppressed |
| Alfuzosin Hcl Er | Alfuzosin Hcl | 22 | suppressed |
| Nitroglycerin | Nitroglycerin | 22 | suppressed |
| Erythromycin | Erythromycin Base | 21 | suppressed |
| Flecainide Acetate | Flecainide Acetate | 21 | suppressed |
| Baclofen | Baclofen | 20 | suppressed |
| Budesonide-Formoterol Fumarate | Budesonide/Formoterol Fumarate | 20 | suppressed |
| Buspirone Hcl | Buspirone Hcl | 20 | suppressed |
| Spironolactone | Spironolactone | 20 | suppressed |
| Trulance | Plecanatide | 20 | suppressed |
| Ultra-Fine Mini Pen Needle | Pen Needle, Diabetic | 20 | suppressed |
| Novolog Flexpen | Insulin Aspart | 19 | suppressed |
| Latanoprost | Latanoprost | 18 | suppressed |
| Single Use Swab | Alcohol Antiseptic Pads | 18 | suppressed |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 18 | suppressed |
| Wixela Inhub | Fluticasone Propion/Salmeterol | 18 | suppressed |
| Cefuroxime | Cefuroxime Axetil | 17 | 14 |
| Gemfibrozil | Gemfibrozil | 17 | suppressed |
| Repaglinide | Repaglinide | 17 | suppressed |
| Rizatriptan | Rizatriptan Benzoate | 17 | suppressed |
| Atenolol-Chlorthalidone | Atenolol/Chlorthalidone | 16 | suppressed |
| Enalapril Maleate | Enalapril Maleate | 16 | suppressed |
| Humalog Kwikpen U-100 | Insulin Lispro | 16 | suppressed |
| Hydralazine Hcl | Hydralazine Hcl | 16 | suppressed |
| Levocetirizine Dihydrochloride | Levocetirizine Dihydrochloride | 16 | suppressed |
| Calcium Acetate | Calcium Acetate | 15 | suppressed |
| Divalproex Sodium | Divalproex Sodium | 15 | suppressed |
| Dorzolamide-Timolol | Dorzolamide Hcl/Timolol Maleat | 15 | suppressed |
| Fenofibrate | Fenofibrate | 15 | suppressed |
| Folic Acid | Folic Acid | 15 | suppressed |
| Methimazole | Methimazole | 15 | suppressed |
| Amlodipine-Valsartan | Amlodipine Besylate/Valsartan | 14 | suppressed |
| Anoro Ellipta | Umeclidinium Brm/Vilanterol Tr | 14 | suppressed |
| Breztri Aerosphere | Budesonide/Glycopyr/Formoterol | 14 | suppressed |
| Clobetasol Propionate | Clobetasol Propionate | 14 | suppressed |
| Digoxin | Digoxin | 14 | suppressed |
| Memantine Hcl Er | Memantine Hcl | 14 | suppressed |
| Mounjaro | Tirzepatide | 14 | suppressed |
| Nano 2nd Gen Pen Needle | Pen Needle, Diabetic | 14 | suppressed |
| Oxycodone-Acetaminophen | Oxycodone Hcl/Acetaminophen | 14 | suppressed |
| Ranolazine Er | Ranolazine | 14 | suppressed |
| Zoloft | Sertraline Hcl | 14 | suppressed |
| Betamethasone Dipropionate | Betamethasone Dipropionate | 13 | suppressed |
| Ciclopirox | Ciclopirox Olamine | 13 | suppressed |
| Combivent Respimat | Ipratropium/Albuterol Sulfate | 13 | suppressed |
| Lidocaine-Prilocaine | Lidocaine/Prilocaine | 13 | suppressed |
| Metronidazole | Metronidazole | 13 | suppressed |
| Risperidone | Risperidone | 13 | suppressed |
| Terazosin Hcl | Terazosin Hcl | 13 | suppressed |
| Verapamil Er | Verapamil Hcl | 13 | suppressed |
| Bupropion Xl | Bupropion Hcl | 12 | suppressed |
| Calcitriol | Calcitriol | 12 | suppressed |
| Clonidine Hcl | Clonidine Hcl | 12 | suppressed |
| Fluoxetine Hcl | Fluoxetine Hcl | 12 | suppressed |
| Lactulose | Lactulose | 12 | suppressed |
| Lovastatin | Lovastatin | 12 | suppressed |
| Pregabalin | Pregabalin | 12 | suppressed |
| Cefprozil | Cefprozil | 11 | suppressed |
| Cinacalcet Hcl | Cinacalcet Hcl | 11 | suppressed |
| Dutasteride | Dutasteride | 11 | suppressed |
| Lidocaine | Lidocaine | 11 | suppressed |
| Nebivolol Hcl | Nebivolol Hcl | 11 | suppressed |
| Nitrofurantoin | Nitrofurantoin Macrocrystal | 11 | suppressed |
| Rytary | Carbidopa/Levodopa | 11 | suppressed |
| Topiramate | Topiramate | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $150.43 · 7 records | Exact Sciences Corporation | AIRSUPRA, Cologuard Collection Kit, Ozempic, Rybelsus | 3 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Ozempic play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with AstraZeneca Pharmaceuticals LP?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error